fda warning letter compounding semaglutide october 2025 Drug Recalls and Warnings: Recalls for Compounded and Tirzepatide, Wegovy; Facility Letters Congress Introduces SAFE Drugs Act
Description
Expanded FDA Indications In 2024/2025 The potential uses for GLP-1s are expanding rapidly, moving well beyond their original purpose of diabetes management
GLP-1 receptor agonists like semaglutide and tirzepatide suppress appetite so effectively that caloric intake drops 16-39%
Proven Results Clinical trials have demonstrated significant weight reduction in many patients using GLP-1 and dual GLP-1/GIP therapies when combined with lifestyle changes
Our goal is to ensure you feel confident and supported as you navigate your personalized weight loss program
They will contact you to talk about the study, or others that may be right for you
Your body takes longer to digest high-protein foods like meat, legumes and dairy
